Related Experiment Video
Updated: Sep 30, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma
Xiao-Jie Liang1, Xin-Yu Song2, Jia-Lin Wu3
1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract:
As the most common subtype of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL) is characterized by a huge degree of clinical and prognostic heterogeneity. Currently, there is an urgent need for highly specific and sensitive biomarkers to predict the therapeutic response of DLBCL and assess which patients can benefit from systemic chemotherapy to help develop more precise therapeutic regimens for DLBCL. Systems biology (holistic study of diseases) is more comprehensive in quantifying and identifying biomarkers, helps addressing major biological problems, and possesses high accuracy and sensitivity. In this article, we provide an overview of research advances in DLBCL prognostic biomarkers made using the multi-omics approach of genomics, transcriptomics, epigenetics, proteomics, metabonomics, radiomics, and the currently developing single-cell technologies.
Related Concept Videos
02:02Genomics
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...